<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02758288</url>
  </required_header>
  <id_info>
    <org_study_id>5150278</org_study_id>
    <nct_id>NCT02758288</nct_id>
  </id_info>
  <brief_title>BK Virus Post-Kidney Transplant: New Practice Versus Traditional Approach</brief_title>
  <official_title>BK Viremia and BK Virus Nephropathy Post Kidney Transplant Comparison of New Practices With Traditional Approach: A Combined Retrospective Chart Review and Prospective Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Loma Linda University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Loma Linda University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigator's aim in this study is to evaluate the impact of a new standard of care
      protocol for the treatment of BK viremia and nephropathy (BKVAN), which includes switching
      from Tacrolimus to equivalent dose of Cyclosporine in patients who have been diagnosed with
      BK viremia or BKVAN based on their viral load, overall graft function (estimated glomerular
      filtration rate), acute rejection, and rate of graft loss due to rejection or BKVAN.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be a combined retrospective chart review and prospective observational study.
      This will be a single center project that will take place at Loma Linda University Transplant
      Institute. All adult kidney recipients who are determined to have BK viremia with a BK PCR
      viral load over 500 copy post-transplant and meet the inclusion criteria but no exclusion
      criteria will be enrolled and observed per study protocol.

      All kidney transplant recipients are routinely assessed for BK virus nephropathy and viremia
      post transplant as part of their standard care. Patients with BK viremia or BK virus
      nephropathy will have adjustments in their immunosuppressive medication based on current
      guidelines and recommendations which include reduction in immunosuppression, treatment with
      medications with antiviral activity (Cidofovir, Ciprofloxacin, Leflunomide, IVIG) or
      switching from a Tacrolimus (Prograf)-based regimen to a Cyclosporine-based regimen.
      Retrospectively, the investigator will collect data on patients who have been diagnosed with
      BK viremia or BK virus nephropathy and have had such a management in past 66 months (from
      1/1/2010 till 06/30/2015). Prospectively, the investigator will enroll and collect data on
      patients who will be treated for BK viremia or BK virus nephropathy.

      As standard of care, all kidney transplant recipients will be seen routinely on
      weekly-biweekly basis in post-transplant clinic for up to 3 months then every 3 months for up
      to a year and yearly thereafter. All kidney transplant recipients will be monitored for BK
      viremia by having blood PCR tested on a monthly basis at 1, 2, 3, 6, and 12 months after
      transplant. Also, all patients post-kidney transplant will be tested for BK viremia if there
      is an acute rise in their creatinine.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Kidney function to compare effectiveness of a new care protocol for the treatment of BK viremia (BK PCR viral load over 500 copy) and BKVAN (confirmed by kidney biopsy) with a similar cohort treated with traditional methods.</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of BK nephropathy in both treatment groups confirmed by kidney biopsy</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of acute cellular or humoral rejection in both treatment groups confirmed by kidney biopsy</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of graft loss in both group as determined by elevated creatinine level and kidney biopsy</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated glomerular filtration rate (eGFR) at start of the study (0) , 3, 6, 12 and 24 months between two groups</measure>
    <time_frame>3, 6, 12, 24 months</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">170</enrollment>
  <condition>BK Virus Infection</condition>
  <condition>BK Virus Nephropathy</condition>
  <arm_group>
    <arm_group_label>New Protocol to treat BK viremia or BKVAN</arm_group_label>
    <description>Adult kidney recipients who are determined to have BK viremia with a BK PCR viral load over 500 copy post-transplant treated with a new treatment protocol, prospective data collection approach</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Protocol to treat BK viremia or BKVAN</arm_group_label>
    <description>Adult kidney recipients who are determined to have BK viremia with a BK PCR viral load over 500 copy post-transplant treated with a traditional standard of care protocol, retrospective data collection approach</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>New Protocol - BK viremia or BK virus nephropathy</intervention_name>
    <description>Data collected prospectively that will follow new clinical practice guidelines that were developed by Loma Linda Nephrology group with collaboration with Transplant surgeons to improve care of patients complicated with BK viremia or BK virus nephropathy.</description>
    <arm_group_label>New Protocol to treat BK viremia or BKVAN</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard Protocol - BK viremia or BK virus nephropathy</intervention_name>
    <description>Data collected retrospectively that followed standard clinical practice guidelines that were developed by Loma Linda Nephrology group with collaboration with Transplant surgeons to improve care of patients complicated with BK viremia or BK virus nephropathy.</description>
    <arm_group_label>Standard Protocol to treat BK viremia or BKVAN</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult kidney recipients who are determined to have BK viremia post-transplant
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age â‰¥ 18 years

          -  Recipient of kidney or combined kidney and pancreas

               -  BK viremia confirmed with blood PCR test with viral load over 500

               -  BK virus nephropathy confirmed by kidney biopsy

        Exclusion Criteria:

          -  Recipient of combined organ transplant except kidney and pancreases

          -  Patient age &lt; 18 years

          -  If patient does not consent for kidney biopsy

          -  Currently on treatment for acute rejection

          -  Patients with HIV, Hep C or Hep B infection

          -  Patients who are on other immunosuppression beside our standard regimen which includes
             Prograf, cellcept / Myfortic and prednisone
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amir Abdipour, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Loma Linda University Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amir Abdipour, MD</last_name>
    <phone>(909) 558-4906</phone>
    <email>AAbdipou@llu.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Loma Linda University Medical Center</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amir Abdipour, MD</last_name>
      <phone>909-558-4906</phone>
      <email>AAbdipou@llu.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Tonelli M, Wiebe N, Knoll G, Bello A, Browne S, Jadhav D, Klarenbach S, Gill J. Systematic review: kidney transplantation compared with dialysis in clinically relevant outcomes. Am J Transplant. 2011 Oct;11(10):2093-109. doi: 10.1111/j.1600-6143.2011.03686.x. Epub 2011 Aug 30.</citation>
    <PMID>21883901</PMID>
  </reference>
  <reference>
    <citation>Port FK, Wolfe RA, Mauger EA, Berling DP, Jiang K. Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients. JAMA. 1993 Sep 15;270(11):1339-43.</citation>
    <PMID>8360969</PMID>
  </reference>
  <reference>
    <citation>Schnuelle P, Lorenz D, Trede M, Van Der Woude FJ. Impact of renal cadaveric transplantation on survival in end-stage renal failure: evidence for reduced mortality risk compared with hemodialysis during long-term follow-up. J Am Soc Nephrol. 1998 Nov;9(11):2135-41.</citation>
    <PMID>9808102</PMID>
  </reference>
  <reference>
    <citation>Padgett BL, Walker DL. Prevalence of antibodies in human sera against JC virus, an isolate from a case of progressive multifocal leukoencephalopathy. J Infect Dis. 1973 Apr;127(4):467-70.</citation>
    <PMID>4571704</PMID>
  </reference>
  <reference>
    <citation>Bressollette-Bodin C, Coste-Burel M, Hourmant M, Sebille V, Andre-Garnier E, Imbert-Marcille BM. A prospective longitudinal study of BK virus infection in 104 renal transplant recipients. Am J Transplant. 2005 Aug;5(8):1926-33.</citation>
    <PMID>15996241</PMID>
  </reference>
  <reference>
    <citation>Ginevri F, Azzi A, Hirsch HH, Basso S, Fontana I, Cioni M, Bodaghi S, Salotti V, Rinieri A, Botti G, Perfumo F, Locatelli F, Comoli P. Prospective monitoring of polyomavirus BK replication and impact of pre-emptive intervention in pediatric kidney recipients. Am J Transplant. 2007 Dec;7(12):2727-35. Epub 2007 Oct 1.</citation>
    <PMID>17908275</PMID>
  </reference>
  <reference>
    <citation>Brennan DC, Agha I, Bohl DL, Schnitzler MA, Hardinger KL, Lockwood M, Torrence S, Schuessler R, Roby T, Gaudreault-Keener M, Storch GA. Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. Am J Transplant. 2005 Mar;5(3):582-94. Erratum in: Am J Transplant. 2005 Apr;5(4 Pt 1):839.</citation>
    <PMID>15707414</PMID>
  </reference>
  <reference>
    <citation>Kadambi PV, Josephson MA, Williams J, Corey L, Jerome KR, Meehan SM, Limaye AP. Treatment of refractory BK virus-associated nephropathy with cidofovir. Am J Transplant. 2003 Feb;3(2):186-91.</citation>
    <PMID>12614296</PMID>
  </reference>
  <reference>
    <citation>Moscarelli L, Caroti L, Antognoli G, Zanazzi M, Di Maria L, Carta P, Minetti E. Everolimus leads to a lower risk of BKV viremia than mycophenolic acid in de novo renal transplantation patients: a single-center experience. Clin Transplant. 2013 Jul-Aug;27(4):546-54. doi: 10.1111/ctr.12151. Epub 2013 Jun 13.</citation>
    <PMID>23758330</PMID>
  </reference>
  <reference>
    <citation>Araya CE, Garin EH, Neiberger RE, Dharnidharka VR. Leflunomide therapy for BK virus allograft nephropathy in pediatric and young adult kidney transplant recipients. Pediatr Transplant. 2010 Feb;14(1):145-50. doi: 10.1111/j.1399-3046.2009.01183.x. Epub 2009 Mar 31.</citation>
    <PMID>19344337</PMID>
  </reference>
  <reference>
    <citation>Williams JW, Javaid B, Kadambi PV, Gillen D, Harland R, Thistlewaite JR, Garfinkel M, Foster P, Atwood W, Millis JM, Meehan SM, Josephson MA. Leflunomide for polyomavirus type BK nephropathy. N Engl J Med. 2005 Mar 17;352(11):1157-8.</citation>
    <PMID>15784677</PMID>
  </reference>
  <reference>
    <citation>Leung AY, Chan MT, Yuen KY, Cheng VC, Chan KH, Wong CL, Liang R, Lie AK, Kwong YL. Ciprofloxacin decreased polyoma BK virus load in patients who underwent allogeneic hematopoietic stem cell transplantation. Clin Infect Dis. 2005 Feb 15;40(4):528-37. Epub 2005 Jan 21.</citation>
    <PMID>15712075</PMID>
  </reference>
  <reference>
    <citation>Randhawa PS. Anti-BK virus activity of ciprofloxacin and related antibiotics. Clin Infect Dis. 2005 Nov 1;41(9):1366-7; author reply 1367.</citation>
    <PMID>16206122</PMID>
  </reference>
  <reference>
    <citation>Hirsch HH, Vincenti F, Friman S, Tuncer M, Citterio F, Wiecek A, Scheuermann EH, Klinger M, Russ G, Pescovitz MD, Prestele H. Polyomavirus BK replication in de novo kidney transplant patients receiving tacrolimus or cyclosporine: a prospective, randomized, multicenter study. Am J Transplant. 2013 Jan;13(1):136-45. doi: 10.1111/j.1600-6143.2012.04320.x. Epub 2012 Nov 8.</citation>
    <PMID>23137180</PMID>
  </reference>
  <reference>
    <citation>Renner FC, Dietrich H, Bulut N, Celik D, Freitag E, Gaertner N, Karoui S, Mark J, Raatz C, Weimer R, Feustel A. The risk of polyomavirus-associated graft nephropathy is increased by a combined suppression of CD8 and CD4 cell-dependent immune effects. Transplant Proc. 2013 May;45(4):1608-10. doi: 10.1016/j.transproceed.2013.01.026.</citation>
    <PMID>23726630</PMID>
  </reference>
  <reference>
    <citation>Huang G, Chen LZ, Qiu J, Wang CX, Fei JG, Deng SX, Li J, Chen GD, Zhang L, Fu Q, Zeng WT, Zhao DQ. Prospective study of polyomavirus BK replication and nephropathy in renal transplant recipients in China: a single-center analysis of incidence, reduction in immunosuppression and clinical course. Clin Transplant. 2010 Sep-Oct;24(5):599-609. doi: 10.1111/j.1399-0012.2009.01141.x.</citation>
    <PMID>19925472</PMID>
  </reference>
  <reference>
    <citation>Knoll GA, Bell RC. Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: meta-analysis of randomised trials. BMJ. 1999 Apr 24;318(7191):1104-7.</citation>
    <PMID>10213717</PMID>
  </reference>
  <reference>
    <citation>Alghamdi S, Nabi Z, Skolnik E, Alkorbi L, Albaqumi M. Cyclosporine versus tacrolimus maintenance therapy in renal transplant. Exp Clin Transplant. 2011 Jun;9(3):170-4.</citation>
    <PMID>21649564</PMID>
  </reference>
  <reference>
    <citation>Gardner SD, Field AM, Coleman DV, Hulme B. New human papovavirus (B.K.) isolated from urine after renal transplantation. Lancet. 1971 Jun 19;1(7712):1253-7.</citation>
    <PMID>4104714</PMID>
  </reference>
  <reference>
    <citation>Boothpur R, Brennan DC. Human polyoma viruses and disease with emphasis on clinical BK and JC. J Clin Virol. 2010 Apr;47(4):306-12. doi: 10.1016/j.jcv.2009.12.006. Epub 2010 Jan 8. Review.</citation>
    <PMID>20060360</PMID>
  </reference>
  <reference>
    <citation>Elphick GF, Querbes W, Jordan JA, Gee GV, Eash S, Manley K, Dugan A, Stanifer M, Bhatnagar A, Kroeze WK, Roth BL, Atwood WJ. The human polyomavirus, JCV, uses serotonin receptors to infect cells. Science. 2004 Nov 19;306(5700):1380-3.</citation>
    <PMID>15550673</PMID>
  </reference>
  <reference>
    <citation>Monaco MC, Jensen PN, Hou J, Durham LC, Major EO. Detection of JC virus DNA in human tonsil tissue: evidence for site of initial viral infection. J Virol. 1998 Dec;72(12):9918-23.</citation>
    <PMID>9811728</PMID>
  </reference>
  <reference>
    <citation>Rinaldo CH, Tylden GD, Sharma BN. The human polyomavirus BK (BKPyV): virological background and clinical implications. APMIS. 2013 Aug;121(8):728-45. doi: 10.1111/apm.12134. Epub 2013 Jun 19. Review.</citation>
    <PMID>23782063</PMID>
  </reference>
  <reference>
    <citation>Balba GP, Javaid B, Timpone JG Jr. BK polyomavirus infection in the renal transplant recipient. Infect Dis Clin North Am. 2013 Jun;27(2):271-83. doi: 10.1016/j.idc.2013.02.002. Epub 2013 Apr 17. Review.</citation>
    <PMID>23714340</PMID>
  </reference>
  <reference>
    <citation>Nickeleit V, Klimkait T, Binet IF, Dalquen P, Del Zenero V, Thiel G, Mihatsch MJ, Hirsch HH. Testing for polyomavirus type BK DNA in plasma to identify renal-allograft recipients with viral nephropathy. N Engl J Med. 2000 May 4;342(18):1309-15.</citation>
    <PMID>10793163</PMID>
  </reference>
  <reference>
    <citation>Vasudev B, Hariharan S, Hussain SA, Zhu YR, Bresnahan BA, Cohen EP. BK virus nephritis: risk factors, timing, and outcome in renal transplant recipients. Kidney Int. 2005 Oct;68(4):1834-9.</citation>
    <PMID>16164661</PMID>
  </reference>
  <reference>
    <citation>Randhawa P, Ho A, Shapiro R, Vats A, Swalsky P, Finkelstein S, Uhrmacher J, Weck K. Correlates of quantitative measurement of BK polyomavirus (BKV) DNA with clinical course of BKV infection in renal transplant patients. J Clin Microbiol. 2004 Mar;42(3):1176-80.</citation>
    <PMID>15004071</PMID>
  </reference>
  <reference>
    <citation>Kahan AV, Coleman DV, Koss LG. Activation of human polyomavirus infection-detection by cytologic technics. Am J Clin Pathol. 1980 Sep;74(3):326-32.</citation>
    <PMID>6251715</PMID>
  </reference>
  <reference>
    <citation>Hirsch HH, Randhawa P; AST Infectious Diseases Community of Practice. BK virus in solid organ transplant recipients. Am J Transplant. 2009 Dec;9 Suppl 4:S136-46. doi: 10.1111/j.1600-6143.2009.02904.x.</citation>
    <PMID>20070673</PMID>
  </reference>
  <reference>
    <citation>Hariharan S. BK virus nephritis after renal transplantation. Kidney Int. 2006 Feb;69(4):655-62. Review.</citation>
    <PMID>16395271</PMID>
  </reference>
  <reference>
    <citation>Drachenberg CB, Hirsch HH, Ramos E, Papadimitriou JC. Polyomavirus disease in renal transplantation: review of pathological findings and diagnostic methods. Hum Pathol. 2005 Dec;36(12):1245-55. Epub 2005 Oct 19. Review.</citation>
    <PMID>16311117</PMID>
  </reference>
  <reference>
    <citation>Hirsch HH, Steiger J. Polyomavirus BK. Lancet Infect Dis. 2003 Oct;3(10):611-23. Review.</citation>
    <PMID>14522260</PMID>
  </reference>
  <reference>
    <citation>Binet I, Nickeleit V, Hirsch HH, Prince O, Dalquen P, Gudat F, Mihatsch MJ, Thiel G. Polyomavirus disease under new immunosuppressive drugs: a cause of renal graft dysfunction and graft loss. Transplantation. 1999 Mar 27;67(6):918-22.</citation>
    <PMID>10199744</PMID>
  </reference>
  <reference>
    <citation>Ramos E, Drachenberg CB, Papadimitriou JC, Hamze O, Fink JC, Klassen DK, Drachenberg RC, Wiland A, Wali R, Cangro CB, Schweitzer E, Bartlett ST, Weir MR. Clinical course of polyoma virus nephropathy in 67 renal transplant patients. J Am Soc Nephrol. 2002 Aug;13(8):2145-51.</citation>
    <PMID>12138148</PMID>
  </reference>
  <reference>
    <citation>Ronco C. Biomarkers for acute kidney injury: is NGAL ready for clinical use? Crit Care. 2014 Dec 10;18(6):680. doi: 10.1186/s13054-014-0680-0.</citation>
    <PMID>25672254</PMID>
  </reference>
  <reference>
    <citation>Han SB, Cho B, Kang JH. BK virus-associated hemorrhagic cystitis after pediatric stem cell transplantation. Korean J Pediatr. 2014 Dec;57(12):514-9. doi: 10.3345/kjp.2014.57.12.514. Epub 2014 Dec 31. Review.</citation>
    <PMID>25653684</PMID>
  </reference>
  <reference>
    <citation>Nickeleit V, Hirsch HH, Zeiler M, Gudat F, Prince O, Thiel G, Mihatsch MJ. BK-virus nephropathy in renal transplants-tubular necrosis, MHC-class II expression and rejection in a puzzling game. Nephrol Dial Transplant. 2000 Mar;15(3):324-32. Review.</citation>
    <PMID>10692517</PMID>
  </reference>
  <reference>
    <citation>Cekmen MB, Bakirdoven S, Sayan M, Yilmaz A. BK virus nephropathy developing after renal transplantation and its treatment with ciprofloxacin: a case report. Transplant Proc. 2012 Dec;44(10):3044-7. doi: 10.1016/j.transproceed.2012.03.059.</citation>
    <PMID>23195024</PMID>
  </reference>
  <reference>
    <citation>Chalasani G, Li Q, Konieczny BT, Smith-Diggs L, Wrobel B, Dai Z, Perkins DL, Baddoura FK, Lakkis FG. The allograft defines the type of rejection (acute versus chronic) in the face of an established effector immune response. J Immunol. 2004 Jun 15;172(12):7813-20.</citation>
    <PMID>15187165</PMID>
  </reference>
  <reference>
    <citation>Zaman RA, Ettenger RB, Cheam H, Malekzadeh MH, Tsai EW. A novel treatment regimen for BK viremia. Transplantation. 2014 Jun 15;97(11):1166-71. doi: 10.1097/01.TP.0000441825.72639.4f.</citation>
    <PMID>24531848</PMID>
  </reference>
  <reference>
    <citation>Hoppe-Seyler K, Sauer P, Lohrey C, Hoppe-Seyler F. The inhibitors of nucleotide biosynthesis leflunomide, FK778, and mycophenolic acid activate hepatitis B virus replication in vitro. Hepatology. 2012 Jul;56(1):9-16. doi: 10.1002/hep.25602. Epub 2012 Jun 1.</citation>
    <PMID>22271223</PMID>
  </reference>
  <reference>
    <citation>Aldred KJ, Kerns RJ, Osheroff N. Mechanism of quinolone action and resistance. Biochemistry. 2014 Mar 18;53(10):1565-74. doi: 10.1021/bi5000564. Epub 2014 Mar 7. Review.</citation>
    <PMID>24576155</PMID>
  </reference>
  <reference>
    <citation>Mateo R, Cho Y, Singh G, Stapfer M, Donovan J, Kahn J, Fong TL, Sher L, Jabbour N, Aswad S, Selby RR, Genyk Y. Risk factors for graft survival after liver transplantation from donation after cardiac death donors: an analysis of OPTN/UNOS data. Am J Transplant. 2006 Apr;6(4):791-6.</citation>
    <PMID>16539637</PMID>
  </reference>
  <reference>
    <citation>Matsuoka L, Shah T, Aswad S, Bunnapradist S, Cho Y, Mendez RG, Mendez R, Selby R. Pulsatile perfusion reduces the incidence of delayed graft function in expanded criteria donor kidney transplantation. Am J Transplant. 2006 Jun;6(6):1473-8.</citation>
    <PMID>16686773</PMID>
  </reference>
  <reference>
    <citation>Johnston TD, Thacker LR, Jeon H, Lucas BA, Ranjan D. Sensitivity of expanded-criteria donor kidneys to cold ischaemia time. Clin Transplant. 2004;18 Suppl 12:28-32.</citation>
    <PMID>15217404</PMID>
  </reference>
  <reference>
    <citation>Israni AK, Salkowski N, Gustafson S, Snyder JJ, Friedewald JJ, Formica RN, Wang X, Shteyn E, Cherikh W, Stewart D, Samana CJ, Chung A, Hart A, Kasiske BL. New national allocation policy for deceased donor kidneys in the United States and possible effect on patient outcomes. J Am Soc Nephrol. 2014 Aug;25(8):1842-8. doi: 10.1681/ASN.2013070784. Epub 2014 May 15.</citation>
    <PMID>24833128</PMID>
  </reference>
  <reference>
    <citation>Duan KI, Englesbe MJ, Volk ML. Centers for Disease Control 'high-risk' donors and kidney utilization. Am J Transplant. 2010 Feb;10(2):416-20. doi: 10.1111/j.1600-6143.2009.02931.x. Epub 2009 Dec 2.</citation>
    <PMID>19958324</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2016</study_first_submitted>
  <study_first_submitted_qc>April 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2016</study_first_posted>
  <last_update_submitted>March 8, 2018</last_update_submitted>
  <last_update_submitted_qc>March 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Kidney transplant</keyword>
  <keyword>BK Viremia</keyword>
  <keyword>BK Nephropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

